Novartis (VTX:NOVN) has been assigned a CHF 88 price target by equities researchers at Kepler Capital Markets in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. Kepler Capital Markets’ target price would indicate a potential upside of 13.70% from the company’s current price.
A number of other analysts have also issued reports on NOVN. Morgan Stanley set a CHF 88 target price on shares of Novartis and gave the stock a “buy” rating in a research report on Friday, October 20th. UBS Group set a CHF 78 target price on shares of Novartis and gave the stock a “neutral” rating in a research report on Monday, October 23rd. JPMorgan Chase & Co. set a CHF 84 target price on shares of Novartis and gave the stock a “neutral” rating in a research report on Friday, December 29th. Barclays set a CHF 80 target price on shares of Novartis and gave the stock a “sell” rating in a research report on Thursday, January 25th. Finally, Credit Suisse Group set a CHF 77 target price on shares of Novartis and gave the stock a “neutral” rating in a research report on Wednesday, January 24th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of CHF 88.19.
Shares of Novartis (NOVN) opened at CHF 77.40 on Friday. The company has a market cap of $200,910.00 and a P/E ratio of 25.46. Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.
COPYRIGHT VIOLATION NOTICE: “Kepler Capital Markets Analysts Give Novartis (NOVN) a CHF 88 Price Target” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/11/kepler-capital-markets-analysts-give-novartis-novn-a-chf-88-price-target.html.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.